New Co-Chairs of the Towards an HIV Cure initiative announced 1 March 2018
(Geneva, Switzerland) – The International AIDS Society (IAS) today announced the appointments of Professor Sharon Lewin and Dr Mark Dybul as the new Co-Chairs of the Towards an HIV Cure Advisory Board. The outgoing Co-Chairs
are long-time leaders in HIV research, Jack Whitescarver and Françoise Barré-Sinoussi.
Lewin is an IAS Governing Council member, Director of the Peter Doherty Institute for Infection and Immunity, and Professor of Medicine at
the University of Melbourne, Australia. Dybul is Faculty Co-Director of the Center for Global Health and Quality and Professor in the Department of Medicine at Georgetown University Medical Center in Washington D.C, USA. He recently stepped down from a five-year
tenure as Executive Director of the Global Fund To Fight AIDS, Tuberculosis and Malaria.
“I am honoured to be taking the IAS Towards an HIV Cure initiative forward at a time when there is renewed excitement in the field,” Lewin
said. “Since 2012 we have come a long way. The rapid advances in HIV cure research have presented clear opportunities for increased engagement between HIV researchers and other disciplines.
“We’ve most recently seen the coming
together of the HIV cure and cancer fields, and I have no doubt that as we accelerate the pace of discovery in HIV cure research, we will continue to see more collaborations of this kind. That we are at this point in such a short timeframe is in large part
due to the tremendous leadership of our previous Co-Chairs – on behalf of the IAS, I would like to thank Jack Whitescarver and Françoise Barré-Sinoussi for their commitment.”
The toolbox of interventions for fighting
the HIV pandemic has grown massively since Barré-Sinoussi co-discovered the virus in 1983. A cure has remained beyond our grasp, but research to develop a cure for HIV or long-term remission has been promising. It has spurred researchers, advocates
and community members to continue making progress.
“We’ve seen extraordinary progress made in treating and preventing HIV over the past 35 years, but in the long term, researchers and policy makers understand that to seriously
bend the trajectory of the epidemic, we are going to need something approximating a cure for HIV,” Dybul said.
“The IAS Towards an HIV Cure initiative is to be lauded for ensuring that HIV cure research has a seat at the
global health table. I am delighted to be part of this next phase and look forward to working with such a remarkable group of scientists and policy makers in the coming years.”
The Towards an HIV Cure initiative is committed to leveraging
a well-informed, multidisciplinary network of stakeholders to advocate for and ensure the prioritization of HIV cure in the global health agenda. It is overseen by a Towards an HIV Cure Advisory Board of experts representing governments, UN agencies, civil society organizations and foundations. The board provides strategic advice and engages stakeholders in
the initiative’s long-term strategy to inform global policy, programmes and funding.
To that end, the mission of the IAS Towards an HIV Cure initiative is to drive concerted efforts to accelerate global scientific research and engagement
towards a cure for HIV.
The first Towards an HIV Cure: Global Scientific Strategy was published in Nature Reviews Immunology in 2012. This, with its Full Recommendations, presented the
first global overview and strategic plan for HIV cure research.
Since 2012, the initiative has convened its annual Towards an HIV Cure Symposium to provide researchers with an opportunity to present and discuss novel strategies for advancing
and overcoming challenges in HIV cure research.
This year, the IAS is partnering with international and local civil society organizations to organize an interactive one-day research literacy workshop as an AIDS 2018 pre-conference
event to provide accessible information on current research directions, emerging collaborations with fields beyond HIV, and challenges for an HIV cure.
The initiative has also focused its efforts on advancing the HIV cure field in resource-limited
settings. An Advocacy-for-Cure
Academy will be organized in Uganda and a Research-for-Cure Academy will take place in South Africa; these award fellowships to outstanding candidates interested in working in HIV cure in resource-limited settings.
Leading infectious diseases expert Professor Sharon Lewin is the inaugural Director of the Doherty Institute. She is also a Professor of Medicine at The University of Melbourne and a National Health and Medical
Research Council (NHMRC) Practitioner Fellow. As an infectious diseases physician and basic scientist, her laboratory focuses on basic, translational and clinical research aimed at finding a cure for HIV and understanding the interaction between HIV and hepatitis
B virus. Her laboratory is funded by the NHMRC, the National Institutes of Health, The Wellcome Trust, the American Foundation for AIDS Research and multiple commercial partnerships.
Lewin has authored more than 230 publications and given
more than 100 major international invited talks on HIV cure. She was the local Co-Chair for the 20th International AIDS Conference in Melbourne, the largest health conference ever held in Australia. She is: chair of the Ministerial Advisory Committee for Blood
Borne Viruses and Sexually Transmitted Infections, the peak advisory committee to the Federal Minister for Health; a member of the NHMRC Council; and an elected member of the Governing Council of the International AIDS Society representing the Asia-Pacific
region. Lewin was a foundation council member of the Australian Academy for Health and Medical Research. She was named Melburnian of the Year in 2014, and in 2015, was awarded the Peter Wills Medal by Research Australia.
Mark Dybul, MD, is the Faculty Co-Director of the Center for Global Health and Quality and Professor in the Department of Medicine at Georgetown University Medical Center in Washington D.C, USA. He has worked on HIV and public health for more than 25 years
as a clinician, scientist, teacher and administrator, most recently as the Executive Director of the Global Fund to Fight AIDS, Tuberculosis and Malaria.
After graduating from Georgetown Medical School, Dybul joined the National Institute
of Allergy and Infectious Diseases as a research fellow under Director Dr Anthony Fauci, where he conducted basic and clinical studies on HIV virology, immunology and treatment optimization, including the first randomized, controlled trial with combination
antiretroviral therapy in Africa. Dybul was a founding architect in the formation of the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR). After serving as Chief Medical Officer, Assistant and Deputy and Acting Director, he was appointed as its
leader in 2006, becoming U.S. Global AIDS Coordinator.